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http://dx.doi.org/10.1016/j.ccr.2014.05.006SUMMARYPLK4 was identified as a promising therapeutic target through a systematic approach that combined RNAi
screening with gene expression analysis in human breast cancers and cell lines. A drug discovery program
culminated in CFI-400945, a potent and selective PLK4 inhibitor. Cancer cells treatedwith CFI-400945 exhibit
effects consistent with PLK4 kinase inhibition, including dysregulated centriole duplication, mitotic defects,
and cell death. Oral administration of CFI-400945 tomice bearing human cancer xenografts results in the sig-
nificant inhibition of tumor growth at doses that are well tolerated. Increased antitumor activity in vivo was
observed in PTEN-deficient compared to PTEN wild-type cancer xenografts. Our findings provide a rationale
for the clinical evaluation of CFI-400945 in patients with solid tumors, in particular those deficient in PTEN.INTRODUCTION
Genomic instability is a characteristic that drives the disease
process of almost all human cancers (Hanahan and Weinberg,
2011). Loss-of-function mutations in tumor protein 53 (TP53),
ataxia telangiectasiamutated (ATM), breast cancer 1, early onset
(BRCA1), and breast cancer 2, early onset (BRCA2) lead to
genomic instability and predispose tissues to the development
of various malignancies, including breast cancer (Wooster and
Weber, 2003). More recently, phosphatase and tensin homolog
(PTEN), which encodes a lipid and protein phosphatase and is
one of the most frequently inactivated tumor suppressor genes,
has been functionally linked to ATM and the DNA damage
response (Bassi et al., 2013). Additionally, reduced expression
of PTEN in breast tumors correlates with genomic instability
(Bose et al., 2002; Puc et al., 2005). Cancer cells have adapted
to tolerate the effects of genomic instability, and these adapta-
tions may represent vulnerabilities that can be exploited for the
design of cancer cell-selective therapies. An example of such a
dependency, now directed to therapeutic use, is the sensitivitySignificance
Solid tumors are an enormous cancer burden and a major ther
man breast cancer, PLK4 was identified as a candidate target
led to the identification of CFI-400945, a selective and orally a
400945 recapitulated pharmacologically many of the hallmark
significant antitumor activity as a single agent in a variety of pre
These results show that CFI-400945 may hold promise as an eof BRCA1 and BRCA2 defective cells to poly (ADP-ribose) poly-
merase (PARP) inhibitors (Bryant et al., 2005; Farmer et al.,
2005).
The unique Polo-like kinase family member, Polo-like kinase 4
(PLK4), is a conserved upstream regulator of centriole duplica-
tion (Bettencourt-Dias et al., 2005; Habedanck et al., 2005).
Depletion of PLK4 by RNAi leads to centriole duplication arrest,
and conversely, overexpression of PLK4 causes centrosome
amplification by production of excessive centrioles (Betten-
court-Dias et al., 2005; Habedanck et al., 2005; Kleylein-Sohn
et al., 2007; Peel et al., 2007). PLK4 is a low-abundance
serine/threonine protein kinase present only in proliferating
normal tissues, but is aberrantly expressed in breast cancer,
as well as other tumor types (Chng et al., 2008; Hu et al., 2006;
Macmillan et al., 2001; Miller et al., 2005; Salvatore et al.,
2007; van de Vijver et al., 2002). Dysregulation of PLK4 expres-
sion causes loss of centrosome numeral integrity, thereby pro-
moting genomic instability (Basto et al., 2008; Ganem et al.,
2009; Holland et al., 2010; Ko et al., 2005; Liu et al., 2012; Mac-
millan et al., 2001), but also potentially enabling cancer cells toapeutic challenge. Using multidimensional data sets for hu-
for the development of anticancer therapeutics. This finding
ctive inhibitor of PLK4. Treatment of cancer cells with CFI-
s of PLK4 kinase inhibition. CFI-400945 was shown to have
clinical tumormodels, including those with PTEN deficiency.
ffective therapeutic for patients with solid tumors.
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recently been discovered between PLK4 and PTEN in breast
cancer cells, suggesting that PTEN-deficient cancer cells are
dependent on PLK4 for survival (Brough et al., 2011). Together,
these findings pointed to PLK4 as a rational target for the devel-
opment of anticancer therapeutics. We therefore initiated a drug
discovery program to identify a potent and selective small mole-
cule inhibitor of PLK4.
RESULTS
Breast Cancer Cells Are Dependent on Polo-like
Kinase 4
PLK4 was identified as a candidate therapeutic target for breast
cancer through a systematic approach that combined functional
RNAi analysis with gene expression analysis in breast cancer-
derived cell line models (unpublished data) and the examination
of available annotated gene expression data sets of breast can-
cer tissue samples (Hu et al., 2006; Miller et al., 2005; van de
Vijver et al., 2002). In the small interfering RNA (siRNA) screen,
14 breast cancer and immortalized cell lines were transfected
with a 96-well-plate-arrayed siRNA library targeting 778 kinase
and kinase-related genes (see Supplemental Experimental Pro-
cedures available online). We selected this gene subset to
screen initially, given the inherent pharmacological tractability
of kinases. After 5 days, cell viability was estimated by
measuring the total protein content using the Sulforhodamine
B (SRB) assay. The data were standardized by the use of a
robust Z score statistic (Zhang, 2011), where a Z score of 0 rep-
resents no effect on cell viability, and negative Z scores repre-
sent loss of cell viability. We used a Z score % 2 to define a
significant loss of cell viability. Reduction of Polo-like kinase 1
(PLK1) most frequently resulted in a loss of cell viability (13/14
cell lines; 93%). Several other mitotic kinases that have already
been the focus of drug discovery programs were also identified
as important for cell viability in the siRNA screen, including
checkpoint kinase 1 (9/14 cell lines; 64%), WEE1 homolog
(S. pombe) (7/14 cell lines; 50%), and cyclin-dependent kinase
1 (7/14 cell lines; 50%). Of note, the siRNA screen was not de-
signed, and was thus underpowered, to identify genetic depen-
dencies of breast cancer cells.
The effects of PLK4 siRNA yielded a Z score % 2 in 7/14
cell lines, suggesting that breast cancer cells may be signifi-
cantly dependent on PLK4 for survival (Figure 1A). Examination
of the microarray data sets demonstrated that PLK4 was over-
expressed in 26% of all breast tumors and in 48% of triple-
negative/basal-like (TNBC) tumors (Figure 1B), the subtype
considered to be the most genomically unstable class of
breast cancer (Shah et al., 2012). Of note, reduction of PLK4
yielded a Z score % 2 in 4/4 TNBC cell lines and 2/2 immor-
talized basal breast cell lines. Quantitative RT-PCR was used
to compare PLK4 mRNA levels in breast cancer cell lines
to those in primary human mammary epithelial cells (HMEC)
derived from normal breast tissue samples. This analysis
demonstrated that PLK4 levels are significantly higher in
breast cancer cells relative to their normal tissue counterparts
(Figure 1C).
RNAi-mediated depletion of PLK4 in cultured breast cancer
cells prevented centriole duplication and induced cell death (Fig-164 Cancer Cell 26, 163–176, August 11, 2014 ª2014 Elsevier Inc.ures S1A and S1B). To explore the effect of reducing PLK4 levels
on the growth of breast cancer cells in vivo, MDA-MB-468 cells
were transduced with either a PLK4 small hairpin (shRNA) vector
or control shRNA vector and introduced subcutaneously into the
contralateral flanks of mice, such that tumors would be exposed
to identical conditions. The transduction of MDA-MB-468 cells
with the PLK4 shRNA-encoding construct led to the reduction
of PLK4 transcript levels in these cells by approximately 60%
compared to that of the control cells prior to implantation. The
reduced PLK4 levels resulted in a significant decrease in in vivo
growth of breast cancer xenografts (PLK4 shRNA tumor xeno-
grafts versus control shRNA tumor xenografts, tumor growth in-
hibition [TGI] = 58%, p = 0.0058) (Figure 1D).
CFI-400945 Is a PLK4-Selective Inhibitor
Based on these studies, we initiated a drug discovery program
that identified CFI-400945 as a potent and selective small mole-
cule inhibitor of PLK4 (Figure 2A; Sampson et al., 2012, 2014). In
an assay using recombinant human PLK4, CFI-400945 inhibited
PLK4 with an IC50 value of 2.8 ±1.4 nM (n = 16) and was ATP
competitive with a Ki value of 0.26 ± 0.1 nM. Consistent with
these results, CFI-400945 inhibited autophosphorylation of
PLK4 at serine 305 with an EC50 value of 12.3 nM in cells overex-
pressing PLK4 (Figures 2B-2D). PLK4 serine 305 autophosphor-
ylation occurs as a consequence of kinase activation and thus
enables identification of active PLK4 in cells (Sillibourne et al.,
2010). To evaluate selectivity, CFI-400945 was profiled against
a broad panel of recombinant protein and lipid kinases, including
clinically relevantmutant kinases. Of the 290 kinases tested, only
ten showed >50% inhibition and no significant inhibitory activity
was observed against other PLK family members (PLK1, PLK2,
and PLK3 IC50s > 50 mM). Based on data from the initial screen,
IC50 values were determined by a 9-point titration curve analysis
for thirteen of the most potently inhibited kinases (Table S1).
There were 11 kinases that displayed IC50 values of less than
100 nM.
Phospho-specific antibodies and cell lines, either endoge-
nously or ectopically expressing the kinase of interest, were
used to examine the inhibition of putative targets of CFI-400945
in a cellular context (Figure 2D). EC50 values of 510 nM and
102 nM were determined for the mitotic kinases, aurora kinase
A (AURKA), and aurora kinase B (AURKB), respectively, in noco-
dazole-arrestedHCT116colorectal cancer cells treatedwithCFI-
400945 and MG132. Activities against neurotrophic tyrosine
kinase, receptor, type 1 (TRKA), neurotrophic tyrosine kinase, re-
ceptor, type 2 (TRKB), and TEK tyrosine kinase, endothelial (Tie2/
TEK) were determined with exogenous protein in transfected
HCT116 cells, and the EC50 values were determined to be
84 nM, 88 nM, and 117 nM, respectively. For c-ros oncogene 1,
receptor tyrosine kinase (ROS), and fibroblast growth factor
receptor 1 (FGFR1), activity in the in vitro kinase screen did not
correlate with activity against the cellular kinases. An EC50 value
of 466 nM was measured for ROS kinase using the HCC78 non-
small cell lung cancer cell line, which expresses a constitutively
active SLC34A2-ROS fusion (Rikova et al., 2007). An EC50 mea-
surement of 1.1 mM was determined for FGFR1 in NIH 3T3 cells
stimulated with basic fibroblast growth factor. Overall, these re-
sults indicate that CFI-400945 selectively inhibits PLK4 in cells,
but has activity against AURKB, TRKA, TRKB, and Tie2/TEK.
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Figure 1. Breast Cancer Cells Are Dependent on PLK4
(A) Waterfall plot of PLK4 siRNA Z scores across the panel of breast cancer cell lines.
(B) Results from our analysis of data fromHu et al. (2006) and represent percent up frequency based onPLK4 overexpression greater than three SD of themean of
normals, with fold change in tumors versus normal (Ratio) for all breast cancers and subtypes.
(C) Expression of PLK4 in breast cancer cell lines and normal breast cells. b-ActinmRNA level was used for data normalization. Data are represented as mean ±
SD from three independent experiments.
(D) MDA-MB-468 breast cancer cells were infected with retroviruses expressing shRNAs against either PLK4 (shPLK4) or luciferase (shLUC), and injected
subcutaneously into the contralateral flanks of CD-1 Nude mice (n = 5). shPLK4 tumor xenografts versus shLUC tumor xenografts, TGI = 58%, p = 0.0058. Data
are represented as mean ± SEM. The p value was calculated using Student’s t test.
See also Figure S1.
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Figure 2. CFI-400945 Is a PLK4-Selective
Inhibitor
(A) The chemical structure of CFI-400945.
(B) HCT116 cells transfected with FLAG-tagged
full-length PLK4 were treated with CFI-400945 at
the indicated concentrations for 4 hr. Lysates were
analyzed by immunoblot analysis with antibodies
against phospho-PLK4 Ser305, FLAG, and glyc-
eraldehyde-3-phosphate dehydrogenase.
(C) U2OS cells transfected with GFP-tagged full-
length PLK4were treated with 500 nMCFI-400945
or DMSO for 4 hr. Cells are stained with an anti-
body against phospho-PLK4 Ser305 and 4’,6-di-
amidino-2-phenylindole (DAPI). Scale bar, 5 mm.
(D) EC50 of CFI-400945 against cellular kinases.
See also Table S1.
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PLK4 kinase activity is required for the precise control of
centriole number, which is critical to maintain genome integrity
(Bettencourt-Dias et al., 2005; Habedanck et al., 2005). To
examine the effect of CFI-400945 on centriole number, U2OS
osteosarcoma cells were treated with the compound, and
the number of centrioles present at the spindle poles of mitotic
cells was determined by immunostaining for centrin2, a marker
for centrioles, and for a-tubulin to visualize the mitotic spindle.
After 15 hr exposure, R200 nM CFI-400945 caused a
decrease in mean centriole number in asynchronous U2OS
cells, whereas 10–100 nM CFI-400945 caused an increase in
mean centriole number relative to control cells, which have 2
centrioles per spindle pole (Figure 3A). Virtually identical results
were obtained for the MDA-MB-468 and MDA-MB-231 breast
cancer cell lines (Figures S2A and S2B). The decrease in
centriole number to one per spindle pole phenocopies the
effect of RNAi-mediated reduction of PLK4 levels and was
observed at 500 nM CFI-400945, strongly suggesting that
this effect is due to complete inhibition of PLK4 kinase activity
by CFI-400945. By contrast, the AURKB-selective inhibitor
AZD1152, which does not inhibit PLK4 (data not shown; Kara-
man et al., 2008), had no effect on centriole number, indicating
that the reduction in centriole number by CFI-400945 is not
due to its inhibitory activity against AURKB. The extent of
centriole overduplication was dose dependent, with a mean
number of centrioles per spindle pole of 2.5 at 10 nM, 3.2 at
50 nM, and 3.5 at 100 nM CFI-400945 compared to 2 for con-
trol cells. Even with excessive centrioles, cells treated with
CFI-400945 at these concentrations formed bipolar spindles,
as the extra centrioles remained engaged to the mother
centriole.166 Cancer Cell 26, 163–176, August 11, 2014 ª2014 Elsevier Inc.To examine the effect of CFI-400945 on
centriole overduplication during the sec-
ond mitosis, asynchronous U2OS, MDA-
MB-468, and MDA-MB-231 cells were
treated for 30 hr (Figures 3B, S2A, and
S2B). Exposure to 10–100 nM CFI-
400945 resulted in a dose-dependent in-
crease in mean centriole number per
spindle pole compared to control cells,
but at this later time point led to the for-mation of aberrant multipolar spindles in all three cell lines. Multi-
polar cells were also generated with R200 nM CFI-400945;
however, each spindle pole only contained a single centriole.
CFI-400945-induced failure of cells to complete cytokinesis (Fig-
ure S2C), likely due to AURKB inhibition, resulted in the formation
of multipolar cells at higher inhibitor concentrations. Consistent
with these results in mitotic cells, defects in centriole duplication
were also seen in interphase cells (data not shown). Together,
these data demonstrate that with either inhibition of centriole
duplication or centriole overduplication, CFI-400945 caused
aberrant mitoses eventually leading to cell death or cell arrest
(discussed below).
The extra centrioles induced by CFI-400945 treatment were
arranged around a central centriole and are reminiscent of the
centriole rosettes formed as a result of PLK4 overexpression
(Habedanck et al., 2005; Kleylein-Sohn et al., 2007) or mutation
of autophosphorylation sites required for PLK4 self-catalyzed
destruction (Guderian et al., 2010; Holland et al., 2012). This
raised the possibility that the overduplication of centrioles
observed at lower concentrations of CFI-400945 may be caused
by an increase in protein levels of partially active PLK4. To deter-
mine if treatment with CFI-400945 affects levels of PLK4 protein,
U2OS cells treated with CFI-400945 for 24 hr were examined by
immunofluorescence microscopy for PLK4 and for centrin2. As
previously reported (Habedanck et al., 2005), we observed
endogenous PLK4 to be localized to centrioles. PLK4 localiza-
tion was unchanged following CFI-400945 treatment, but the
abundance of PLK4 at centrioles was significantly increased.
Levels of PLK4 at the centriole increased 2-fold relative to the
DMSO control when cells were treated with 50 nM CFI-
400945, a concentration at which centriole amplification is
induced, and 3.5-fold with 500 nM CFI-400945, a concentration
BA
Figure 3. CFI-400945 Causes Centriole Duplication Defects in Cancer Cells
Treatment of U2OS cells with CFI-400945 for 15 hr (A) and 30 hr (B) causes centriole overduplication at 10, 50, and 100 nM, but inhibits centriole duplication at 200
and 500 nM. Upper panels: mitotic figures of cells treated with CFI-400945, AZD1152, or DMSO. Cells are stained with centrin2 (centriole marker), a-tubulin, and
DAPI. Insets show higher magnification views of the centrioles at the spindle pole (boxed regions). Scale bars, 5 mm; 0.5 mm for insets. Lower panels: graph of the
percentage of spindle poles in mitotic cells containing the indicated number of centrioles. Data are representative of three independent experiments, with a total
of 60 cells for (A) and 50 cells for (B) examined per treatment condition in each experiment, respectively. See also Figure S2.
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Figure 4. CFI-400945 Increases the PLK4 Protein Level at Centrioles
Left: images show the levels of PLK4 at centrioles in U2OS cells at interphase
after 24 hr of treatment with CFI-400945 or DMSO. Cells are stained with
centrin2, PLK4, and DAPI. Insets show higher magnification views of the
centrioles (boxed regions). Scale bars, 5 mm; 0.5 mm for insets. Of note, the
centrioles are arranged together in interphase cells.
Right: graph of the quantification of PLK4 immunofluorescence staining at
centrioles. Data are represented as mean fold change ± SEM relative to the
DMSO control from two independent experiments, with a total of 100 cells
examined per treatment condition.
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with these results in interphase cells, increases in the level of
PLK4 at centrioles were also observed in mitotic cells (data not
shown).
We evaluated the effect of CFI-400945 on growth inhibition
(GI50) in a panel of breast cancer cell lines after 5 days (Table
S2). There were two distinct outcomes that were observed; a
subset of the cell lines died (GI50 = 14165 nM; e.g., MDA-
MB-468), and by contrast, other cell lines continued to undergo
endoreduplication before arresting (GI50 > 1,000 nM; e.g., MDA-
MB-231) (Figures 5A and 5B and Table S3). The majority of the
cell lines with low GI50 values were PTEN deficient (9/14 cell
lines). There were 2 PTEN-deficient cell lines and 15/20 PTEN
wild-type cell lines that hadGI50 values > 1,000 nM (p = 0.005 be-
tween PTEN-deficient and PTEN wild-type groups; the PTEN
mutation inMDA-MB-453 cells is predicted to be a low functional
impact mutation; Table S3). The relationships between PLK4
mRNA levels, TP53 status, or doubling time of the cell lines
and response to CFI-400945 were also examined. PLK4 has
been reported to be transcriptionally repressed by p53 (Li
et al., 2005). No correlation was observed between these
features and response to CFI-400945. Comparable effects of
CFI-400945 were observed on the growth of ovarian, colorectal,
glioblastoma, lung, prostate, and pancreatic cancer cell lines
(data not shown).
We focused our efforts toward testing CFI-400945 in breast
cancer cell lines, as our panel is comprehensively annotated
with representation of various PTEN alterations, and thus
allowed for the evaluation of PTEN as a candidate predictive
biomarker for CFI-400945. The differential responses to CFI-168 Cancer Cell 26, 163–176, August 11, 2014 ª2014 Elsevier Inc.400945 treatment are highlighted by results for MDA-MB-468
and MDA-MB-231 cells. After 2 days, CFI-400945 caused the
accumulation of cells with R4N DNA content, indicating that
DNA replication continued to occur in the absence of cytoki-
nesis (Figure 5C). An endoreduplication effect has been re-
ported with AURKB inhibition (Gully et al., 2010; Harrington
et al., 2004), and we observe a similar DNA content profile
with AZD1152, suggesting that this effect of CFI-400945 is
likely due to its inhibition of AURKB. CFI-400945-induced cell
death in cancer cell lines is driven, at least in part, by
apoptosis. An increase in activated caspase-3/7 was observed
in MDA-MB-468 cells 2 days after treatment with CFI-400945
(Figure 5D). By contrast, a minimal increase in activated cas-
pase-3/7 was observed with treatment of MDA-MB-231 cells.
Since MDA-MB-231 cells are sensitive to CFI-400945, as
evident by the dysregulation of centriole number and the induc-
tion of polyploidy, we examined whether death in this cell line
may be delayed. Cell cycle analysis of MDA-MB-231 cells after
3, 5, and 8 days of treatment with CFI-400945 indicated that
these cells completed several rounds of endoreduplication
without significant cell death before the cells arrested as large
polyploid cells with 32N DNA content (Figure S3A). Notably,
normal HMEC cells were less responsive to CFI-400945 than
cancer cell lines (Figures 5D and S3B; Table S3). To further
substantiate that PTEN is a possible synthetic lethal partner
of CFI-400945, we showed that increased cell death is
observed with MDA-MB-231 cells transfected with PTEN
siRNAs and treated with CFI-400945 compared to control cells
(Figure S3C).
In Vivo Characterization of the Anticancer Potential
of CFI-400945
The tolerability and pharmacokinetic (PK) properties of CFI-
400945 were initially evaluated in mice. To determine a tolerable
dose range for in vivo efficacy studies, mice were given orally
CFI-400945 for 21 days, with doses ranging from 2.5–
20 mg/kg. The maximum tolerated dose (MTD) for once-daily
(QD) administration of CFI-400945 was estimated to be 7.5–
9.5 mg/kg, defined as the highest dose that did not cause loss
in body weight R 20% or overt toxicity (i.e., signs of ill health
or abnormal behaviors, including hunched posture, poor groom-
ing, urine stains, diarrhea, and dehydration) in accordance with
institutional humane endpoint guidelines. Dosing within this
range was subsequently employed and found to be well toler-
ated in multiple tumor xenograft models and strains of mice.
Similarly, MTDs of 13.5 mg/kg and 52 mg/kg were estimated
for twice-weekly (2 days on/5 days off) and once-weekly (QW)
schedules, respectively.
In addition to the observations defining tolerability listed
above, a comprehensive histopathological analysis has been
performed on mice given orally 7.5 mg/kg CFI-400945 QD for
21 days, with no significant findings observed in any organ or
tissue. Moreover, comprehensive rising and repeat dose toxico-
logic evaluation in rats and dogs has been completed for CFI-
400945 as part of the Investigational New Drug-enabling phase
of compound development. In summary, dose-limiting toxicities
were found to be reversible gastrointestinal effects and myelo-
suppression, which are strongly consistent with the proposed
mechanism of action of the molecule (Table S4). The toxicology
AB D
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(legend on next page)
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potential as an effective treatment in oncology.
PK analysis was performed by treating mice with single oral
doses of CFI-400945 ranging from 3.75–104 mg/kg. The doses
were chosen to encompass the doses used for efficacy studies
employing QD (7.5 mg/kg) and QW (52 mg/kg) schedules.
Plasma was obtained at specified time points, and concentra-
tions of CFI-400945 were determined by liquid chromatog-
raphy-tandem mass spectrometry. CFI-400945 was absorbed
rapidly after oral administration, reachingmaximum plasma con-
centrations (Cmax) of 0.25–11.68 mg/mL for the doses tested.
Over the >25-fold dose range, there was a linear dependence
of exposure (both area under the curve and Cmax) relative to
dose (Figure S4A). Elimination half-lives ranged between 3.7–
4.2 hr between 3.75–26 mg/kg, but were longer with increasing
doses (5.4 and 6.9 hr at 52 and 104 mg/kg, respectively).
An isogenic pair of HCT116 colorectal cancer cell lines, PTEN
wild-type and PTEN null, were established as xenografts to eval-
uate the effect of the PTEN presence on the in vivo efficacy of
CFI-400945 (Figure 6A). CFI-400945 given orally QD showed
higher activity in the PTEN null xenografts (TGI = 103%, regres-
sion = 7%, p = 0.008) compared to both the PTEN wild-type
xenografts (TGI = 57%, p = 0.1) and 5-fluorouracil (5-FU).
In vitro data for this isogenic system also showed, albeit less
dramatically, that CFI-400945 was selective for PTEN deficiency
(p < 0.001; Figure S4B), supporting observations made in the
more genetically diverse breast cancer cell line panel. These re-
sults were extended through the testing of CFI-400945 in mice
bearing MDA-MB-468 (PTEN null) or MDA-MB-231 (PTEN
wild-type) breast tumor xenografts (Figure 6B). The high dose
of CFI-400945 (9.4 mg/kg) showed comparable antitumor activ-
ity in both tumor xenografts (TGI = 77%, p = 0.01 for the MDA-
MB-468 tumor xenografts, and TGI = 73%, p = 0.03 for the
MDA-MB-231 tumor xenografts). However, the low dose of
CFI-400945 (3 mg/kg) showed higher activity in the MDA-MB-
468 tumor xenografts (TGI = 57%, p = 0.03) compared to the
MDA-MB-231 tumor xenografts (TGI = 4%, p = 0.5).
CFI-400945 has demonstrated dose-dependent efficacy in
additional cancer cell line and patient-derived xenograft (PDX)
models across various indications, and representative studies
are described here. Significant antitumor activity for CFI-
400945 was observed in mice bearing SW48 colorectal cancer
xenograft tumors on both a continuous (daily) and intermittent
dosing schedule, underscoring dosing flexibility (Figure S4C).
CFI-400945 was also tested in a PDX model generated from an
estrogen receptor-low, progesterone receptor-negative, human
epidermal growth factor receptor 2-negative (ERlowPRHER2)
high-grade invasive ductal carcinoma that is PTEN null by immu-
nohistochemistry and western blot analyses (Figure 6C). AnFigure 5. Response Profile of CFI-400945 versus Breast Cancer Cell L
(A) After 5 days of treatment, cell growth was determined by measuring total prot
software. p = 0.005 between PTEN-deficient and PTEN wild-type cell lines for G
(B) SRB dose-response curves from MDA-MB-468 and MDA-MB-231 cells after
(C) MDA-MB-468 andMDA-MB-231 cells were treated with CFI-400945, AZD115
content by flow cytometry. Gating indicates 2N (G1), 4N (G2/M), 8N (polyploid),
(D) MDA-MB-468 and MDA-MB-231 breast cancer cells and normal HMEC breas
50 nM CFI-400945 prior to measurement of caspase-3 and caspase-7 activities. D
activation relative to the DMSO control.
See also Figure S3 and Tables S2 and S3.
170 Cancer Cell 26, 163–176, August 11, 2014 ª2014 Elsevier Inc.intermittent dosing schedule was examined, with CFI-400945
given twice weekly to explore alternative schedules that could
be translated to the clinic. Marked tumor regression (TGI =
115%, 82% regression, p = 0.01) was observed following
77 days of dosing of CFI-400945, with complete disappearance
of palpable tumors in 3 of 5 animals. CFI-400945 treatment was
continued and resulted in a durable response throughout the
experiment. By contrast, treatment with carboplatin had no sig-
nificant effect on tumor growth. CFI-400945 was also examined
in carboplatin pretreated mice with large tumors (1,500 mm3)
and substantial tumor regression was observed (59% regression
after 25 days of treatment). CFI-400945 was well tolerated at the
doses and schedules examined, as measured by little to no
decrease in body weight and normal behavior. Together, these
results indicate that CFI-400945 can inhibit the growth of a range
of tumor types and may be effective in a clinical setting even in
advanced tumors.
To determine the pharmacodynamics of CFI-400945 in vivo,
phospho-histone H3 positive cells were counted in the MDA-
MB-468 breast tumor xenografts at day 4 (Figure 7A). Relative
to vehicle controls, a small increase in phospho-histone H3 pos-
itive cells was measured in CFI-400945-treated tumors (2.7%
cells with CFI-400945 treatment compared to 2.1% with vehicle
control treatment). Mitotic profiles were also analyzed. An in-
crease in tumor cells with aberrant mitoses was observed after
CFI-400945 treatment, consistent with observations from cell
culture experiments (11.6% cells with CFI-400945 treatment
compared to 3.5% cells with vehicle control treatment). Immu-
nohistochemistry staining of centrioles in tumor xenografts was
attempted with two different centrin2 antibodies; however,
high background staining was observed in each case, making
this experiment technically challenging. As an alternative
approach, we used an antibody to pericentrin, which marks peri-
centriolar material surrounding centrioles and not centrioles
themselves, to examine centrosome number in the breast tumor
xenografts. In the CFI-400945-treated tumors at day 4, 15.6% of
mitotic cells had a mean of 3.3 centrosomes per cell compared
to vehicle controls, where 96.4% of mitotic cells had a mean of
2 centrosomes per cell (Figure 7B). These data for CFI-400945
in tumors are comparable to those for cancer cells in vitro treated
with 500 nM CFI-400945, where a mean of 3.4 centrosomes per
mitotic cell was observed (Figure 7B). As stated, CFI-400945 in-
hibits AURKB, and this activity likely explains the failure of cancer
cells treated with the inhibitor to complete cytokinesis. This
defect prevents the formation of monopolar cells at higher con-
centrations of CFI-400945 that block centriole duplication in
cancer cells in vitro (Figure 3B; R200 nM). The data for CFI-
400945-treated tumors are distinctly different from those for
cancer cells in vitro treated with lower concentrations of theines
ein content by SRB assay, and GI50 values calculated using GraphPad PRISM
I50 values using the median permutation test.
treatment with CFI-400945 for 5 days. Data are represented as mean ± SD.
2, or DMSO for 48 hr prior to staining with propidium iodide and analysis of DNA
and 16N (polyploid) cells.
t cells were treated in triplicate for the indicated amounts of time with 0, 25, or
ata are represented as mean fold change ± SEM in caspase-3 and caspase-7
Figure 6. In Vivo Characterization of the Anticancer Potential CFI-400945 on Human Xenograft Tumors
(A) Female CD-1 Nude mice with established HCT116 PTEN null xenografts (left panel) were treated for 19 days (n = 8). CFI-400945, 2.5 mg/kg per os (PO, oral
administration), quaque die (QD, once a day) versus vehicle, TGI = 6%, p = 0.8; CFI-400945, 5 mg/kg PO, QD versus vehicle, TGI = 79%, p = 0.02; CFI-400945,
7.5 mg/kg PO, QD versus vehicle, TGI = 103%, regression = 7%, p = 0.008; and 5-FU, 30 mg/kg intraperitoneal administration (IP), QDX5 versus vehicle, TGI =
47%, p = 0.2. Female CD-1 Nude mice with established HCT116 PTEN wild-type xenografts (right panel) were treated for 17 days (n = 8). CFI-400945, 2.5 mg/kg
PO,QD versus vehicle, TGI =9%, p = 0.8; CFI-400945, 5mg/kg PO,QD versus vehicle, TGI = 41%, p = 0.2; CFI-400945, 7.5mg/kg PO,QD versus vehicle, TGI =
57%, p = 0.1; and 5-FU, 30 mg/kg IP, QDX5 versus vehicle, TGI = 40%, p = 0.2. For figure clarity, only data for 7.5 mg/kg CFI-400945 treatments are shown.
(B) Female C.B.-17 SCIDmice with establishedMDA-MB-468 xenografts (left panel) were treated for 20 days (n = 5). CFI-400945, 3mg/kg PO, QD versus vehicle,
TGI = 57%, p = 0.03 and CFI-400945, 9.4 mg/kg PO, QD versus vehicle, TGI = 77%, p = 0.01. Female C.B.-17 SCID mice with established MDA-MB-231
(legend continued on next page)
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5.9 centrosomes per mitotic cell, respectively, was observed
(Figure 7B) and centriole overduplication occurred (Figure 3B).
In the CFI-400945-treated xenograft tumors, examples of mitotic
cells containing the large numbers of extra centrosomes that can
be caused by CFI-400945 at lower concentrations in vitro were
not observed. Together, these data indirectly suggest that the
dominant mechanism of action of CFI-400945 at efficacious
doses is inhibition of centriole duplication, as observed at the
higher concentrations of the compound in vitro.
DISCUSSION
We report here the functional characterization of CFI-400945, a
selective and orally active inhibitor of PLK4 that recapitulates
pharmacologically many of the previously reported effects of
PLK4 loss-of-function studies (Bettencourt-Dias et al., 2005; Ha-
bedanck et al., 2005; Kleylein-Sohn et al., 2007; Peel et al.,
2007). PLK4 kinase activity is essential for the precise control
of centriole number. Dysregulation of centriole duplication by
CFI-400945 results in aberrant mitoses and could be a key
mechanism through which CFI-400945 mediates its antineo-
plastic activity. Control of centriole number by PLK4 is achieved
through the balance between phosphorylation of downstream
substrates and autophosphorylation that regulates PLK4 protein
levels (Brownlee et al., 2011; Holland et al., 2010; Puklowski
et al., 2011). Inhibition by CFI-400945 blocks both these func-
tions of PLK4 kinase activity. Loss of PLK4 autophosphorylation
by CFI-400945 prevents the autoregulated destruction of PLK4,
resulting in an increase in protein levels at the centriole. Inhibition
of PLK4 phosphorylation of its substrates by CFI-400945 blocks
centriole duplication.
CFI-400945 has a bimodal effect on centriole duplication,
inhibiting duplication at high inhibitor concentrations and pro-
moting duplication at low inhibitor concentrations. These obser-
vations may reflect the different consequences between full and
partial inhibition of PLK4 activity by CFI-400945. At concentra-
tions of CFI-400945, where PLK4 is not sufficiently autophos-
phorylated for degradation, but enough activity remains for
PLK4 to phosphorylate its substrates, the increased levels of
PLK4 lead to centriole overduplication. With higher concentra-
tions of CFI-400945, where PLK4 activity is fully inhibited,
centriole duplication is blocked regardless of PLK4 levels. With
either inhibition of centriole duplication or centriole overduplica-
tion, CFI-400945 activity caused aberrant mitoses leading to cell
arrest or cell death.
Mouse plasma concentration-time profiles indicate that
following oral administration of efficacious doses of CFI-
400945 in mice, plasma levels of CFI-400945 were sustained
and remained above both the EC50 value for half-maximal inhibi-
tion of cellular PLK4 autophosphorylation and growth inhibition
GI50 values for 24 hr. Moreover, CFI-400945 demonstratedxenografts (right panel) were treated for 21 days (n = 5). CFI-400945, 3mg/kg PO, Q
vehicle, TGI = 73%, p = 0.03.
(C) Female C.B.-17 SCIDmice with established human breast tumor xenografts we
CFI-400945, 13.5mg/kgPO, 2DaysOn/5DaysOff versus vehicle, TGI = 115%, regr
Dataare representedasmean±SEM(for figureclarity, onlypositiveerrorbarsaresh
See also Figure S4 and Table S4.
172 Cancer Cell 26, 163–176, August 11, 2014 ª2014 Elsevier Inc.dose-dependent antitumor activity. Analysis of xenograft tumors
from mice treated with an efficacious dose of CFI-400945
showed a pharmacodynamic effect that is suggestive of com-
plete rather than partial inhibition of PLK4 kinase activity. This
result is supported by the corresponding PK data for this dose
of CFI-400945 in mice that shows a Cmax over 1 mM, a concen-
tration in cell culture experiments that causes inhibition of
centriole duplication.
Inhibitory effects in cellular contexts were demonstrated for
TRKA, TRKB, Tie2/TEK, and AURKB. Not all of these kinases,
however, have the expression pattern or biological activity that
would account for the effects of CFI-400945 on the cell types
tested here. TRKA and TRKB are highly expressed in neuroblas-
tomas (Nakagawara et al., 1992; Nakagawara et al., 1994). Tie2/
TEK is overexpressed in the microvasculature of solid tumors
(Peters et al., 1998). As for AURKB, it is present in all proliferating
cells and an integral component of the chromosome passenger
protein complex, thus its inhibition is likely to explain some of the
observed effects of CFI-400945 at higher concentrations, and in
particular, defects in cytokinesis and accumulation of polyploid
cells.
The data for PLK4 siRNA from the viability screen and
response profiling of CFI-400945 in breast cancer cell lines did
not perfectly align. This outcome is not unexpected as it is chal-
lenging to reconcile every aspect of siRNA-mediated silencing
with pharmacologic inhibition toward a given target, since siRNA
results in removal of the entire protein, including all noncatalytic
binding and associative functions, whereas only the catalytic
functions are transiently and reversibly inhibited when the com-
pound is employed. Examination of the response of breast can-
cer cell lines to CFI-400945 showed no relationship to the PLK4
mRNA level. There are several possible explanations for this
apparent discordance. PLK4 is aberrantly expressed in a wide
range of tumor types compared with normal tissue. This dysre-
gulation of PLK4 expression is likely to induce genomic instability
in the early stages of tumorigenesis through abnormal centro-
some duplication and the generation of aneuploidy. However,
the events required to promote tumor formation can take years,
so by the time a tumor is detected, the aberrant cells are not
necessarily dependent upon the original driver of the genomic
instability for survival. A similar absence of correlation between
the levels of mitotic kinases and the response to their inhibitors
has been reported for Aurora kinases and PLK1 (Degenhardt
et al., 2010; Glaser et al., 2012; Hook et al., 2012). CFI-400945
causes dysregulated centriole duplication, mitotic errors, and
eventually cell death or cell arrest. These events occur indepen-
dently of PLK4 levels and are likely dependent on the presence of
defective checkpoints and DNA repair mechanisms in tumor
cells.
The profiling of breast cancer cell lines for response to CFI-
400945 suggests that there is a correlation between induction
of cell death and PTEN deficiency. Also, increased in vivo activityD versus vehicle, TGI = 4%, p = 0.5 andCFI-400945, 9.4mg/kg PO, QD versus
re treated for 77 days (n = 5). Vehicle-treatedmice reached endpoint on day 77.
ession = 82%, p= 0.01 andcarboplatin, 75mg/kg IP, QWX2, TGI = 16%, p= 0.3.
own). p valueswerecalculatedusingStudent’s t test.quaque (QW,onceaweek).
AB
Figure 7. In Vivo Effect of CFI-400945 on Human Xenograft Tumors
(A) Effect of CFI-400945 on levels of phospho-histone H3 Ser10 and mitotic divisions in tumor xenografts. C.B.-17 SCID mice with established MDA-MB-468
xenografts were treated with CFI-400945, 9.4 mg/kg PO, QD, or vehicle for 4 days (n = 3); mice were sacrificed and tumor tissue removed 4 hr after the final dose.
(legend continued on next page)
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type tumor models. These findings link response to CFI-400945
treatment and PTEN status and are supported by the recent
identification of PLK4 as an essential gene in PTEN-deficient
breast cancer cells (Brough et al., 2011). Together, these data
suggest that CFI-400945 may represent an effective therapeutic
for breast cancers, including those deficient in PTEN, and
provide the basis for the clinical testing of this hypothesis. Eval-
uation of PTEN deficiency and other candidate predictive bio-
markers for CFI-400945 early in clinical development could
lead to an enrichment strategy for a subgroup of patients pre-
dicted to be responders. Loss of PTEN function in breast cancer
can occur either by PTEN mutation (approximately 5% of tu-
mors; Saal et al., 2008) or by reduction of PTEN expression
(almost 50% of tumors; Bose et al., 2002; Depowski et al.,
2001; Perren et al., 1999). Nuclear PTEN is required for DNA
repair (Bassi et al., 2013), and genomic instability is frequently
observed in breast cancers with low expression of PTEN (Bose
et al., 2002; Puc et al., 2005). Deregulation of centriole duplica-
tion by CFI-400945 results in aberrant mitoses and could exac-
erbate the genomic instability in PTEN-deficient cells and drive
cell death. As might be expected, the profiling revealed that
with CFI-400945 treatment there were PTEN wild-type cell lines
that died, and conversely, PTEN-deficient cell lines that arrested
as large polyploid cells. These results likely reflect PTEN-inde-
pendent mechanisms that impact the response of genomically
complex cancer cell lines to CFI-400945. Further validation of
PTEN, identification of additional predictive biomarkers, and
the elucidation of the cellular mechanisms responsible for the
response profile of CFI-400945 in breast cancer cells are
currently under investigation. Importantly, these studies may
portend a more substantial tumor response in difficult-to-treat
patient subpopulations, and thus, this provides a solid rationale
for further characterization and development of CFI-400945.
In summary, CFI-400945 is a potential small molecule inhibitor
for the treatment of cancer with a mechanism of action that in-
volves potent inhibition of PLK4. CFI-400945 has significant anti-
tumor activity in vivo toward breast cancer xenograft models as a
single agent at well-tolerated doses. Health Canada and the FDA
have approved CFI-400945 for human use and a phase 1 clinical
trial has been launched.
EXPERIMENTAL PROCEDURES
Cell Lines
All cell lines were obtained from American Type Culture Collection (ATCC) and
maintained according to the supplier’s instructions (Table S2). Breast cancer
cell line gene expression subtype was as described by Neve et al. (2006)
with the exception of CAL51 and HCC1806 that are of basal B subtype by us-
ing the cancer class prediction of Neve et al. (2006). PTENmutational status in
the breast cancer cell lines was as described by Saal et al. (2008) and theScale bar, 5 mm. Footnotes: (1) data are represented as mean ± SEM of the to
percentage of mitotic cells, with 685, 621, and 593mitotic cells scored for the vehi
400945-treated tumors.
(B) Effect of CFI-400945 on centrosome number in cancer cells and tumor xenogra
CFI-400945 or DMSO for 29 hr. Cells are stained with an antibody against pericen
mitotic figures of immunohistochemistry staining of pericentrin on the xenograft
number of centrosomes per mitotic cell, with a minimum of 40 cells examined per
the Veh, and 188, 261, and 201 cells scored for the CFI-400945-treated tumors. Fo
per mitotic cell.
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base (http://www.sanger.ac.uk/genetics/CGP/cosmic/). TP53mutational sta-
tus in the breast cancer cell lines was as described by the Sanger Institute
COSMIC database,Wasielewski et al. (2006), and Neve et al. (2006). Short tan-
dem repeat (STR) profiling was used to verify authenticity of the cell lines.
There were sixteen STR loci that were simultaneously amplified in a multiplex
PCR reaction (The Hospital for Sick Children), and the ATCC database was
used for comparison, where possible. Cell lines were routinely tested for
mycoplasma and used at low passage numbers (<15). Primary cultures of
normal HMEC were obtained from Lonza and maintained according to the
supplier’s instructions.
Compounds, RNAi, and Plasmids
CFI-400945 was synthesized as described (Sampson et al., 2012). The hydro-
chlorate and fumarate salt forms of CFI-400945 were used in all studies.
AZD1152-hydroxyquinazoline pyrazol anilide was obtained from Astatech.
The siRNA library (siARRAY, containing 778 siRNA pools targeting 518 kinases
and kinase-related human genes) was obtained in 96-well plates from Dhar-
macon. Each well in this library contained a SMARTpool of 4 distinct siRNA
species targeting different sequences of a single gene. The internal control
to monitor transfection efficiency was siTOX (Dharmacon), a proprietary siRNA
that targets genes responsible for apoptosis and cell death. The negative con-
trol was ON-TARGET siSCR (Dharmacon). PTEN siRNA was obtained from
QIAGEN. Cell lines were transfected with Lipofectamine 2000 transfection re-
agent (Invitrogen) according to the supplier’s instructions. Thymidine (2.5 mM),
nocadazole (200 ng/ml), MG132 (0.5 mM), and 5-FUwere obtained fromSigma.
Carboplatin was obtained from Teva Canada. RNAi-Ready-pSIREN-RetroQ-
ZsGreen and RNAi-Ready-pSIREN-RetroQ-ZsGreen-LUC retroviral shRNA
expression vectors were obtained from Clontech Laboratories Inc. The
expression construct encoding full-length human Tie2/TEK was obtained
from Origene. pBOS-H2BGFP expression vector was obtained from BD
Biosciences.
Animals
C.B.-17 SCID and nonobese diabetic scid gamma (NSG) mice were obtained
from the animal colony at the Ontario Cancer Institute of the University Health
Network. CD-1 Nudemice were obtained fromCharles River Laboratories. The
6- to 8-week-old female animals were used for the studies and were allowed
unrestricted access to food and water. The Institutional Animal Care and
Use Committee of the University Health Network approved all animal
procedures.
Xenograft Tumor Growth
The PDX (passage 3) was generated from the primary resection specimen of a
treatment-naive grade 3, ERlowPRHER2 invasive ductal carcinoma that was
obtained from a consenting patient under a research protocol approved by the
University Health Network Research Ethics Board (UHN REB #06-0196-CE).
Xenografts were established by implantation of a fresh tumor fragment (2–
3 mm) into the uncleared mammary fat pat of female NSG mice and serially
propagated by subcutaneous transplantation of tumor fragments in female
C.B.-17 SCID mice. Animals were randomized and treatments were initiated
when tumor volumes reached 250–300 mm3 (9 weeks following implant). Can-
cer cell line xenografts were established by injecting subcutaneously 53 106
13 107 tumor cells into the flank of femalemice. Animals were randomized and
treatments were initiated when tumor volumes reached 100–120mm3. To treat
an established tumor, CFI-400945 and the vehicle (water) were administered
by oral gavage, and 5-FU and carboplatin were administered by intraperitonealtal percentage of cells; (2) data are represented as mean ± SEM of the total
cle control tumors (Veh), and 493, 852, and 363mitotic cells scored for the CFI-
fts. Upper panels: mitotic figures of thymidine-releasedU2OS cells treatedwith
trin (centrosome marker), a-tubulin and DAPI. Scale bar, 5 mm. Middle panels:
tumors in (A). Scale bar, 5 mm. Lower panel: graph of the mean ± SEM of the
treatment condition for U2OS cells, and with 194, 215, and 295 cells scored for
otnote: (1) Percentage of cells with the indicatedmean number of centrosomes
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and tumor volume was measured three times per week. Tumor volume (mm3)
was defined as follows, length3width2/2. Percentage tumor growth inhibition
(% TGI) was defined as follows, 100 3 [1 – (TVf,treated – TVi,treated)/(TVf,control –
TVi,control)], where TVf is the average tumor volume at the end of study, and
TVi is the average tumor volume at the initiation of treatment. In cases where
tumor regression occurred, percentage tumor regression was defined as fol-
lows, 100 3 [1  (TVf,treated/TVi,treated)]. At the completion of the study, the
mice were sacrificed by an anesthetic overdose, and tumor tissue removed
for further studies.
Immunohistochemistry
Formalin-fixed and paraffin-embedded tumors were sectioned and stained for
phospho-histone H3 (Ser10) (Cell Signaling Technology Inc.) or pericentrin
(Abcam) and counter-stained with hematoxylin. Mitotic cells in single sections
were manually scored for mitotic divisions and for centrosome number. Phos-
pho-histone H3 positive cells were counted in viable tumor areas using Aperio
ImageScope and ImageJ analysis software.
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